Open AccessBeneficial metabolic effects of nateglinide versus acarbose in patients with newly‐diagnosed type 2 diabetes 1
Author(s) -
GAO Hongwei,
XIE Chao,
WANG Haining,
LIN Yujing,
HONG Tianpei
Publication year - 2007
Publication title -
acta pharmacologica sinica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.514
H-Index - 90
eISSN - 1745-7254
pISSN - 1671-4083
DOI - 10.1111/j.1745-7254.2007.00534.x
Subject(s) - nateglinide , acarbose , postprandial , medicine , endocrinology , type 2 diabetes , insulin , lipid profile , asymmetric dimethylarginine , crossover study , cholesterol , diabetes mellitus , chemistry , arginine , biochemistry , placebo , alternative medicine , amino acid , pathology
Aim: To investigate the acute and chronic effects of nateglinide versus acarbose on plasma asymmetric dimethylarginine (ADMA) levels and lipid profiles in patients with newly‐diagnosed type 2 diabetes. Methods : A crossover trial of nateglinide and acarbose was conducted on 16 drug‐naïve patients with newly‐diagnosed type 2 diabetes during a total period of 9 weeks. Plasma glucose, serum insulin, free fatty acids (FFA), lipids and lipoproteins, and plasma ADMA were measured. Results : The efficiencies of a single dose of nateglinide (120 mg) and acarbose (50 mg) for lowering postprandial hyperglycemia were similar. Compared to acarbose, nateglinide significantly increased postprandial insulin release after a standard meal test in patients with type 2 diabetes. Nateglinide acutely decreased postprandial 120 min FFA concentrations and 240 min ADMA levels more significantly than acarbose. The fasting high‐density lipoprotein cholesterol level increased and the low‐density lipoprotein cholesterol level decreased significantly, but the fasting levels of triglycerides, total cholesterol, and ADMA were unchanged after 4 weeks of treatment with nateglinide. Acarbose did not affect fasting lipid profiles or the ADMA levels after 4 weeks of treatment. Conclusion : These results suggest that the reduction of postprandial FFA and ADMA concentrations induced by nateglinide may be associated with the partial restoration of early‐phase insulin secretion and may impart a cardiovascular advantage in comparison with acarbose.